There__O are__O a__O range__O of__O indicators__O of__O the__O impact__O of__O the__O research__O and__O outcomes__O described__O in__O this__O Case__B-LOC Study.__I-LOC
These__O include:__O (i)__O granting__O of__O patents__O on__O engineering__O human__O beta-cells__O by__O electrofusion__O with__O growth__O of__O an__O IP__O portfolio__O around__O our__O innovative__O technology;__O (ii)__O licensing__O of__O engineered__O beta-cells__O to__O the__O biopharmaceutical__O industry__O together__O with__O their__O deposit,__O commercialisation__O and__O sales__O through__O ECACC__B-ORG (recently__O retitled__O Public__B-ORG Health__I-ORG England);__I-ORG (iii)__O demonstration__O of__O the__O utility__O of__O our__O cell__O products__O by__O bio-industry__O and__O the__O international__O research__O community__O for__O drug__O discovery__O programmes__O and__O generation__O of__O high__O impact__O publications.__O
Filing__O and__O granting__O of__O initial__O patent__O on__O engineering__O human__O beta-cells__O by__O electrofusion:__O Our__O first__O patent__O entitled__O "Human__B-ORG Insulin__I-ORG Producing__I-ORG Cell__I-ORG Line"__I-ORG that__O described__O our__O human__O clonal__O beta-cell__O products__O was__O filed__O in__O August__O 2000__O and__O subsequently__O granted,__O inherently__O demonstrating__O the__O minimum__O legislative__O criteria__O of__O non-obviousness,__O novelty,__O and__O capability__O of__O being__O applied__O in__O trade/industry.__O
This__O initial__O priority__O filing__O (GB0018808.6)__O led__O to__O growth__O of__O our__O related__O IP__O portfolio__O to__O include__O 2__O granted/issued__O patents__O (covering__O 9__O countries)__O on__O our__O innovative__O electrofusion__O technology__O for__O generation__O of__O clonal__O human__O beta-cells,__O which__O strategically__O allowed__O us__O freedom__O to__O operate__O in__O the__O field,__O and__O provided__O sufficient__O opportunity__O for__O commercialisation__O during__O the__O impact__O reporting__O period__O as__O described__O below.__O
Commercialisation__O and__O impact__O on__O non-academic__O end__O users:__O In__O order__O to__O maximise__O the__O impact__O of__O our__O cells__O and__O allow__O other__O researchers__O and__O industry__O to__O benefit__O from__O their__O availability,__O we__O deposited__O three__O of__O our__O rat__O cells__O (BRIN-BD11,__B-ORG BRIN-BG5,__I-ORG BRIN-BG7),__I-ORG and__O four__O of__O our__O human__O cells__O (1.1B4,__O 1.1E7,__O 1.4E7,__O 1.2B4)__O in__O October__O 2010__O with__O the__O ECACC.__B-MISC
Testament__O to__O the__O impact__O of__O availability__O of__O these__O unique__O cells,__O ECACC__B-ORG has__O been__O impressed__O by__O the__O interest__O and__O uptake__O of__O our__O cells__O by__O both__O research__O scientists__O and__O the__O bio-industry__O (see__O ECACC__B-ORG reference__O letter,__O Section__B-ORG 5__O below).__O
Our__O human__O cells__O and__O rat__O cells__O lodged__O with__O ECACC__B-ORG have__O generated__O 37__O sales__O since__O January__O 2011__O and__O derived__O total__O income__O of__O &#163;23,356.__O
As__O well__O as__O the__O direct__O impact__O on__O ECACC__B-ORG as__O an__O end__O user,__O arising__O from__O sales,__O the__O commercialisation__O of__O our__O 4__O human__O and__O 3__O rodent__O bioengineered__O insulin-secreting__O cell__O lines__O have__O proven__O utility__O as__O commercial__O and__O non-commercial__O research__O tools__O to__O study__O pancreatic__O beta__O cell__O function/dysfunction,__O including__O discovery__O and__O screening__O of__O new__O drugs/targets.__O
As__O detailed__O in__O separate__O Case__O Study,__B-PER Ulster__I-PER has__O developed__O a__O strong__O portfolio__O of__O 12__O granted__O patents__O since__O 2008__O on__O peptide__O therapeutics__O for__O diabetes__O based__O around__O initial__O in__O vitro__O data__O evaluating__O the__O effects__O of__O innovative__O stable__O analogues__O of__O incretin__O gut__O hormones__O (GIP,__B-ORG GLP-1__I-ORG and__O CCK-8)__B-ORG on__O insulin__O secretion__O using__O BRIN-BD11__B-ORG cells.__O
Since__O 2007__O we__O have__O also__O conducted__O contract__O research__O on__O GLP-1__O and__O other__O therapeutic__O gut__O hormones__O using__O BRIN-BD11__B-ORG cells__O for__O [text__O removed__O for__O publication]__O (total__O income__O &#163;555,441).__O
As__O further__O evidence__O of__O the__O direct__O impact__O of__O our__O cells__O on__O end__O users__O in__O industry,__O our__O human__O 1.1B4__O cells__O have__O been__O licensed__O to__O [text__O removed__O for__O publication],__O Sanofi__B-PER Aventis__I-PER and__O Domain__B-PER Therapeutics__I-PER for__O commercial__O use__O (income__O &#163;62,567),__O and__O evaluation__O licenses__O have__O been__O granted__O for__O 8__O other__O pharmaceutical__O companies__O ([text__O removed__O for__O publication],__O Celther__B-ORG Polska,__I-ORG Eli__I-ORG Lilly,__I-ORG Nordic__O Bioscience,__O Novartis,__O [text__O removed__O for__O publication],__O and__O Tranzyme__B-ORG Pharma,).__I-ORG
The__O impact__O of__O our__O human__O cells__O on__O industry__O is__O evidenced__O by__O the__O testimonial__O from__O Domain__B-ORG Therapeutics__I-ORG (see__I-ORG Section__I-ORG 5__O below),__O a__O company__O who__O have__O used__O our__O human__O 1.1E7__O cells__O to__O evaluate__O novel__O GLP-1__B-ORG therapeutics__O for__O diabetes,__O clearly__O stating__O in__O their__O letter__O how__O our__O cells__O have__O impacted__O on__O their__O business.__O
Commercialisation__O and__O impact__O on__O academic__O end-users:__O The__O impact__O of__O recent__O availability__O of__O our__O human__O cells__O and__O sales__O through__O ECACC__B-ORG on__O end__O users__O in__O the__O scientific__O research__O community__O is__O already__O being__O evidenced__O including,__O but__O not__O limited__O to,__O novel__O data__O presented__O in__O original__O papers__O reporting:__O discovery__O of__O molecular__O pathway__O by__O which__O nicotinamide-__O functionalised__O multiwalled__O carbon__O nanotubes__O can__O increase__O human__O beta-cell__O insulin__O production__O (Ilie__B-MISC et__I-MISC al.__O
Int__O J__B-PER Nanomedicine,__I-PER 8,__O 3345-3353)__O using__O our__O human__O 1.4E7__O cells;__O and__O a__O direct__O effect__O of__O hypoxia__O on__O human__O beta-cell__O proliferation__O and__O up-regulation__O of__O Reg__B-ORG and__O HGF__B-ORG genes__O (Ota__O et__O al.__O
Life__B-ORG Sciences,__I-ORG doi:pii:__O S0024-3205(13)00513-4),__O using__O our__O human__O 1.1B4__O cells__O (see__B-ORG Section__I-ORG 5__O below).__O
Other__O details__O of__O impact:__O The__O impact__O that__O this__O research__O has__O had__O in__O the__O field__O of__O diabetes__O is__O also__O evident__O through__O recognition__O and__O esteem.__O
Professor__O PR__O Flatt__O and__O Professor__O NH__O McClenaghan__O (together__O with__O Professor__O FPM__O O'Harte__O (employed__O at__O Ulster__B-LOC since__O 1993)__O were__O winners__O of__O the__O prestigious__O inaugural__O Academic__B-ORG Enterprise__I-ORG Awards__I-ORG (ACES)__I-ORG Europe__I-ORG for__I-ORG Life__I-ORG Sciences__I-ORG presented__O in__O Stockholm,__B-LOC 2008.__O
This__O is__O testimony__O to__O outstanding__O translational__O research__O and__O associated__O commercialisation.__O
Professor__O PR__B-PER Flatt__I-PER was__O elected__O Member__B-ORG Royal__I-ORG Irish__I-ORG Academy__I-ORG (2006)__O and__O awarded__O Dorothy__B-ORG Hodgkin__I-ORG Lecture__I-ORG of__I-ORG Diabetes__I-ORG UK__I-ORG (2007).__O
Professor__O NH__B-PER McClenaghan__I-PER was__O awarded__O the__O Physiology__B-ORG Society__I-ORG Sharpey-__I-ORG Schafer__I-ORG Lecture__I-ORG (2005)__O for__O his__O research__O on__O insulin__O secretion__O and__O beta-cell__O engineering.__O
